No-fault compensation following adverse events attributed to vaccination: a review of international programmes

Clare Looker & Heath Kelly

Abstract
Programmes that provide no-fault compensation for an adverse event following vaccination have been implemented in 19 countries worldwide, the first in Germany in 1961 and the most recent in Hungary in 2005. We performed a review of these programmes and determined elements that were common to all of them: administration and funding, eligibility, process and decision-making, standard of proof, elements of compensation and litigation rights. Most programmes were administered by state or national governments except in Finland and Sweden where they are coordinated by pharmaceutical manufacturers. Although funding is usually from Treasury, Taiwan (China) and the United States of America impose a tax on vaccine doses distributed. Decisions on compensation are made using established criteria or assessed on a case-by-case basis, while the standard of proof required is usually less than that required for court cases. Benefits provided by programmes include medical costs, disability pensions and benefits for noneconomic loss and death. Most countries allow claimants to seek legal damages through the courts or a compensation scheme payout but not both. We conclude that a variety of programmes, based on ethical principles, have been successful and financially viable in developed countries throughout the world. We believe there is a strong argument for widespread implementation of these programmes in other developed countries.

Introduction
The public health benefits of vaccination are clear. The World Health Organization estimates that, in 2008, more than 2.5 million deaths were prevented by vaccination. Immunization programmes have led to the eradication of smallpox, the elimination of poliomyelitis in many regions, and substantial reductions in morbidity and mortality from Haemophilus influenzae type b, diphtheria, whooping cough and tetanus. However vaccines are not without risks and it is commonly accepted that, regardless of proper design, manufacture and delivery, adverse events occur following vaccination although serious adverse events are rare. At a population level, it is considered that these small risks are balanced by the benefits of widespread population immunization. However this means that an individual occasionally bears a significant burden for the benefit provided to the rest of the population. Although these vaccine-related adverse events occur occasionally due to negligence, more often there is no clearly attributable fault. Without evidence of clear negligence, it is difficult to obtain compensation through traditional legal mechanisms. Recognizing this, several countries have implemented vaccine-injury compensation programmes. These programmes reflect a belief that it is fair and reasonable that a community that is protected by a vaccination programme accepts responsibility for and provides compensation to those who are injured by it. In 1999, Evans conducted a thorough review of 13 compensation programmes. We aimed to update this review examining similar programme elements to those described both by Evans and by Mariner in her 1985–6 study.

Search strategy
We used a meta-search engine (Supersearch MetaLib) to identify key published resources on vaccine-injury compensation schemes. Databases searched were: Web of Science, Scopus v.4 (Elsevier), Medline (ISI), CINAHL Plus (EBSCO), PsycINFO* (CSA), PubMed, Academic Search Premier (EBSCO), Expanded Academic ASAP (Gale), JSTOR, LegalTrac (Gale) and Law Journal Library (Hein).

Key words entered were vaccine AND injury AND compensation; “vaccine injury”; vaccine AND damage AND compensation; vaccine AND compensation; “vaccine policy”; “vaccine injury” AND international; and “vaccine injury” AND [country name]. We scanned reference lists of key full text papers. We used citation tracking in PubMed, Google Scholar, ScienceDirect and EBSCOhost to forward track key papers and identify articles cited in mainstream journals. We performed a grey literature search in Google using the same keywords. We searched web pages of international organizations, bilateral agencies, nongovernmental organizations, consultancy firms and universities involved in funding, delivering or evaluating immunization services. We perused national government web sites to find details of specific country’s schemes. Finally we contacted key individuals involved in vaccine compensation programmes throughout the world.

Evolution of programmes
We identified 19 countries with current vaccine compensation schemes (Fig. 1). In 1953, the German Supreme Court ruled that people who were injured by compulsory vaccination (in this case smallpox) were entitled to compensation. Germany enacted a compensation programme in 1961. France implemented a similar scheme in the 1960s. Concern over injuries caused by medicines and the inadequacies of traditional litigation processes increased after the thalidomide tragedy in the 1960s. In the 1970s, concerns over adverse events related to diphtheria–tetanus–pertussis vaccination led to programmes being established in Austria, Denmark, Japan, New Zealand, Sweden Switzerland.
Since Evans’ review there have been several political and socioeconomic shifts that have affected vaccine-injury compensation. Thirteen of the schemes reviewed in this paper are based in Europe, where many countries have since integrated vaccine liability as part of a more comprehensive no-fault approach to medical accidents.24 Furthermore, there is interest in harmonizing health policy within the European Union, illustrated by a recent proposal for a pan-European compensation scheme for injuries caused by defective products.25

A vaccine-injury compensation scheme removes the uncertainty of tort liability for manufacturers and provides a more fair, efficient and stable approach for injured parties. Litigation is an expensive and restricted avenue that is inaccessible for many vaccine recipients. Furthermore, several small vaccine manufacturers left the market.35

A vaccine-injury compensation scheme removes the uncertainty of tort liability for manufacturers and provides a more fair, efficient and stable approach for injured parties. Litigation is an expensive and restricted avenue that is inaccessible for many vaccine recipients. Furthermore, several small vaccine manufacturers left the market.35

Arguments supporting vaccine-injury compensation include political and economic pressures, litigation threats, increasing confidence in population-based vaccine programmes and ensuring sustainability of vaccine supply. However, compensation schemes are also based on underlying principles of fairness and justice.

If there is no formal compensation scheme, the only source of compensation is through the courts, usually under the law of tort. Tort law requires a claimant to prove that he or she has suffered a wrong due to another person’s negligence or deliberate harm. The problem with this process, in the case of vaccination, is that there is often no clearly negligent party. A court-based approach to compensation can be inequitable and unpredictable, resulting in high monetary awards for some, while those who do not seek legal recourse receive nothing.

In the USA, before 1987, those injured by vaccines had no choice but to take their chances in the court system and seek recovery for their injuries directly from the manufacturer.34 Without a compensation system, it became difficult for vaccine manufacturers to predict their exposure to lawsuits. Accordingly, manufacturers and their insurers increased prices based on worst-case estimates.35 This led to exponential price rises, vaccine shortages and a reduction in vaccine research. Furthermore, several small vaccine manufacturers left the market.35

Many countries that have implemented compensation schemes have
Table 1. Common elements of vaccine-injury compensation schemes for six selected countries

<table>
<thead>
<tr>
<th>Common elements</th>
<th>Finland</th>
<th>Germany</th>
<th>New Zealand</th>
<th>Sweden</th>
<th>United Kingdom of Great Britain and Northern Ireland</th>
<th>United States of America</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administration and funding</td>
<td>Manufacturers, distributors, suppliers tax</td>
<td>General revenue of the Lander (state governments)</td>
<td>ACC earner’s account (funded by personal income tax) and ACC non-earner’s account (funded by government)</td>
<td>Percentage levy of member manufacturers’ annual sales</td>
<td>National treasury</td>
<td>Flat-rate tax paid by manufacturers for every childhood vaccine sold</td>
</tr>
<tr>
<td>Eligibility/Vaccines covered</td>
<td>All</td>
<td>All</td>
<td>All</td>
<td>All</td>
<td>Recommendation childhood vaccines, adult influenza, armed forces</td>
<td>Recommendation childhood vaccines, adult influenza, armed forces</td>
</tr>
<tr>
<td>Process and decision-making</td>
<td>Finnish Pharmaceutical Insurance Pool claims officer</td>
<td>Internal Lander office of social recompensation (medical expert consultation)</td>
<td>Review by ACC Treatment Injury Advisory Committee</td>
<td>Claims manager with Zurich insurance</td>
<td>Evaluation by appointed medical officer</td>
<td>Vaccine injury table or proving “causation in fact”</td>
</tr>
<tr>
<td>Standard of proof</td>
<td>Balance of probabilities&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Probable cause</td>
<td>Balance of probabilities&lt;sup&gt;a&lt;/sup&gt;</td>
<td>“Preponderant probability”</td>
<td>Balance of probabilities&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Balance of probabilities&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Elements of compensation</td>
<td>Unreimbursed medical costs, disability pension, noneconomic loss, death benefits</td>
<td>Medical costs, disability pension, funeral costs</td>
<td>Medical costs, disability pension, death benefits</td>
<td>Unreimbursed medical costs, disability pension, death benefits</td>
<td>Lump sum payment</td>
<td>Balance of probabilities&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Litigation rights</td>
<td>No</td>
<td>Limited</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No further civil claim allowed</td>
</tr>
</tbody>
</table>

ACC, Accident Compensation Corporation.
<sup>a</sup> “Causation in fact” considers an injury to be proven if these 3 criteria are met: (i) a medical theory causally connecting the vaccination and the injury; (ii) a logical sequence of cause and effect showing that the vaccination was the reason for the injury; and (iii) a showing of a proximate temporal relationship between vaccination and injury.
<sup>b</sup> Balance of probabilities mean that there is a “preponderance of evidence” or more evidence than not to suggest the vaccine caused the injury. This is a lower burden of proof than “beyond reasonable doubt”.
<sup>c</sup> Between 2001 and 2010 more than 5600 claims were made for autism or autism spectrum disorder caused by measles–mumps–rubella vaccine and thimerosal-containing vaccines. These cases were consolidated into the Omnibus Autism Proceedings. After several test cases, no causal link has been found between autism and the vaccines, however a large number of cases have not yet been formally dismissed or withdrawn from the courts. Given the separate process that has been established for this large number of claims, this data is listed separately in the claims data published by the National Vaccine Injury Compensation Programme in the United States of America. 38
done so as an expression of community solidarity. Ethicist Michelle Mello argues that solidarity means members of a community do not bear the risks of vaccination alone. Vaccine injuries can be severe and complex, and are often suffered by children who require a lifetime of care and may not qualify for other benefits under accident insurance schemes. In a vaccination programme, the injured and uninjured pay unequal shares of the social cost of producing the social good of herd immunity. Mello argues that, in line with principles of fairness and solidarity, mechanisms are needed to prevent the uninjured (unintentionally) “free-riding” on the injured.

**Common programme elements**

From our review of current schemes, we identified six elements common to all schemes: administration and funding, eligibility, process and decision-making, standard of proof, elements of compensation and litigation rights. These elements are similar to those used by Evans in his 1999 review. Key aspects of these elements are summarized in Table 1 for six developed countries with established compensation programmes, selected to demonstrate the variety of approaches to these programmes.

**Administration and funding**

Most compensation schemes are government enacted and run. This usually occurs at a national level, but in Germany and Switzerland the programme is administered by the state (or canton), Quebec, the only province in Canada with a vaccine-injury compensation scheme, administers its programme through the Provincial Ministry of Health and Social Services.

In Scandinavian countries, vaccine-injury compensation is part of broad no-fault compensation schemes for both medical treatment and medicines. In Denmark and Norway, this is administered by the Department of Health, whereas the Finnish and Swedish schemes are voluntary for pharmaceutical companies and are not operated by the government. After the thalidomide disaster in the early 1960s, the international pharmaceutical industry, operating in Sweden, collaborated with the insurance industry and government to establish a Swedish vaccine-injury compensation scheme, to which pharmaceutical companies and importers voluntarily pay contributions. Similarly, in Finland concerns about litigation and justice led to the government proposing a statutory scheme, even drafting an Act, but pharmaceutical manufacturers instead formed the Finnish cooperative for the indemnification of medicine-related injuries and negotiated with the insurance sector to establish its own voluntary scheme. In Norway, although the scheme is government run, it is also funded by contributions from the pharmaceutical industry. In New Zealand, there is no separate administrative entity to address vaccine injuries. Instead these are covered by the broad Accident Compensation Corporation, which is a statutory corporation that provides no-fault compensation for any personal injury and death caused by accident.

The source of funding for vaccine-injury compensation schemes largely reflects where decision-making power lies. Several countries finance their programmes from national, state or municipal treasuries or, in the case of Japan, a mixture of each. Finland, Norway and Sweden use a manufacturers’ levy, New Zealand’s scheme is financed from several sources including levies on employers, employees and motor vehicle owners, government funding and investment returns.

Taiwan (China) and the USA retain centralized government control over their schemes, which are funded from a vaccine tax. In Taiwan (China), a tax of one New Taiwan dollar (US$ 0.034) per vaccine dose is paid by the manufacturer or importer of the vaccine. In the USA, the tax is US$ 0.75 per dose.

In most countries, the compensation schemes are a secondary source of funding for medical and disability expenses. In general, patients receive primary support from the national public or private insurers. The compensation schemes can be relatively modest in size and not need to cover the full range of expenses that might be considered in a tort or product liability case.

**Eligibility**

As noted previously by Evans, there is considerable variation in the vaccines covered by compensation schemes. Some schemes cover only mandatory or recommended vaccines, while others cover all licensed medicines. The United Kingdom and USA cover childhood vaccines, adult influenza and vaccines given to the armed forces. In Italy, compensation is only payable for injuries from one of five mandatory vaccines or from non-mandated vaccines required for travel or employment. Other countries determine eligibility based on occupation (e.g. health care worker), indication (e.g. travel), citizenship and time elapsed between the vaccine and a claim.

All the schemes have threshold injury or disability criteria that need to be met before claiming compensation. In New Zealand, an injury has to be “severe” to be eligible for compensation. In England, compensation is paid when there is greater than 60% disability. Similarly, in Finland to be eligible for compensation an injury must result in a loss of functional ability for at least 14 days. German law only specifies that the injury must exceed a “normal post-vaccinal reaction”, however supplemental payments are conditional on disability existing for at least 6 months.

Evans describes four broad categories of benefits that are provided by vaccine-injury compensation schemes. These are: medical costs, disability pensions, coverage for noneconomic loss and death benefits. With the exception of the United Kingdom with its lump sum payment of 120 000 British pounds sterling, all schemes cover medical expenses, disability pensions and death benefits. These payments are usually proportional to the severity of the vaccine injury. Some countries also cover noneconomic loss including “pain and suffering” and compensation to family. The USA also compensates both successful and unsuccessful claimants for reasonable legal costs.

**Process**

All countries, except Finland and Sweden, have passed legislation to enact their compensation schemes and government departments operate the programmes in most countries. Most schemes require claims to be filed with an administrative body that makes initial eligibility and compensation decisions on claims. Many countries use an administrative process for deciding compensation eligibility and payment amounts. These schemes usually have an internal review process, with the option of external review if a claim is deemed complex or contentious. Proponents of these schemes believe this administrative approach is less adver-
sarial, has lower costs, lessens the need to apportion blame and maximizes the opportunity for those with genuine vaccine injuries to receive just compensation.

While the procedures for filing a claim in the USA are modelled quite closely on the civil litigation process, the scheme includes a process for pre-determining causation if a vaccine injury is included on its vaccine injury table. This process presumes causation if any injury listed in the table occurs within a specified time frame after vaccination. For example, if anaphylaxis occurs within 4 hours of hepatitis B vaccine administration, it is presumed due to the vaccine. While an alternate mechanism exists for injuries which fall outside the table specifications, most claims have been for “on-table” injuries. All countries examined have a formalized appeal process for claimants. In places, including Scandinavia and the USA, appeals can be lodged disputing the size of the compensation payment. Some countries impose time limits on lodging an appeal.

Vaccine-injury compensation schemes aim to streamline the process of receiving compensation. Most countries prioritize the timely resolution of claims, although the processing time varies depending on the size of the scheme and whether the scheme is part of a broader no-fault programme. In New Zealand, the Accident Compensation Corporation has 9 months to make a decision. In the USA, a claim decision takes an average 2–3 years. In France, the Office National d’Indemnisation des Accidents Medicaux has a statutory responsibility to process claims within 6 months.

Standard of proof

No-fault vaccine-injury compensation programmes are based on the premise that the adverse outcome is not attributable to a specific individual or industry but due to an unavoidable risk associated with vaccines. A problem for all compensation schemes is determining whether there is a causal relationship between a vaccine and a specific injury. The method by which causation is proven in tort law can be quite different from the accepted method of establishing causation in science and epidemiology. The most commonly accepted criteria for establishing epidemiological causation are the Bradford Hill criteria. While they do not provide a definitive checklist for assessing causality, these criteria provide a framework for separating causal and non-causal explanations of observed associations. Despite its importance, there is no single, clear consensus on the definition of causation.

In tort litigation the defendant, or defective product, is on trial for “causing” a specific individual’s or group’s adverse outcome. A direct link must be established between the particular action of that defendant or product and the adverse outcome. Legal causation is deterministic and requires proof of an allegation.

In general, most compensation schemes offer a more liberal approach to causation than the strict legal standard. For instance, the Swedish general drug injury compensation scheme requires a “preponderant probability” that an injury was caused by a drug. While apparently reluctant to define this specifically, commentators interpret this as a “slightly more than 50%” chance of a drug having caused an injury.

In New Zealand, vaccine injuries were previously considered “medical misadventures”. This was taken in practice to mean a “medical error” or “medical mishap”. Although both forms of accident were eligible for compensation, the distinction required the Accident Compensation Corporation to investigate whether a vaccine injury was caused by an error or was an adverse outcome of a correctly delivered vaccine. This concept of “medical misadventure” was later replaced with the concept of “treatment injury”. This reflects a more genuine no-fault system, ensuring compensation for injured vaccine recipients regardless of whether the injury is judged avoidable or not. Similarly, in the USA, proof of the level required in the law courts is not necessary to access compensation. One of the key goals of the scheme was simplification of the compensation system for all parties. It was felt that requiring legal causation to be proved would be overly time consuming and laborious.

Litigation rights

To ensure that compensation schemes remain attractive to claimants, they must offer a compensation payment and process that is more appealing than the tort or litigation system. Most countries legislate that claimants can seek either damages through the courts or a compensation scheme payout but not both. Other countries, such as Denmark and the United Kingdom, adjust compensation payments if damages have been received through the courts.

Conclusion

Vaccine-injury compensation programmes are increasingly regarded as an important component of successful vaccination programmes. They have been used for the past 50 years to ensure that individuals who are adversely affected in the interests of protecting the whole community are adequately compensated and cared for. There are a variety of schemes with different structures and approaches in use throughout the world. The schemes function most efficiently when they operate alongside well-established, comprehensive national social welfare systems. In these countries, vaccine-injury compensation schemes have been found to have a relatively low administrative cost, especially compared to civil litigation cases.

In the first decade of the 21st century, acceptance of vaccine-injury compensation has grown. Schemes are being enacted beyond industrialized Europe and North America. The importance of these schemes, based on ethical principles, has been stressed by parent groups, and claimants have reported satisfaction in having received compensation through a streamlined process. Apart from the reluctance of governments to move away from the adversarial approach to providing compensation, we believe there is a strong argument for widespread implementation of these programmes in other developed countries.

Competing interests: None declared.
Clare Looker & Heath Kelly

No-fault compensation following vaccine adverse events

Policy & practice

doi:10.2471/BLT.10.081901

376

Bull World Health Organ 2011;89:371–378

ملخص

التعويض بدون إثبات الخطأ التالي للأحداث الضائرة المنسوبة إلى التلقيح: مراجعة البرامج الدولية

لقد نُفِذَت برامج تقديم التعويضات بدون إثبات الخطأ التالي للأحداث الضائرة المنسوبة إلى التلقيح في 19 دولة حول العالم. كان أولها ألمانيا عام 1961، وأخرها المجر عام 2005. وقد أجرى الباحثون مراجعة لهذا البرنامج ووجدوا المعجزة الشائع تداولها في جميع البرامج: الإدراة والمتابعة، وشروط التأهل للتعويض، وعملية التحليل، وبروتوكولات التعويض، ودعم التأهيل، والحقوق في الدعاوى القضائية. وكانت أغلب البرامج تُدَار عن طريق الولاية أو الحكومة الوطنية، ماعدا في فنلندا والسويد حيث تُدَار من خلال الاقتصاد، بينما تُدَار في الرياضات (مقاطعات الصين، تايوان) والولايات المتحدة الأمريكية على حُسب قوانين التأمين. وتُتَرَبَّض لجنيف على نطاق واسع في مدار البلدان المتن良く.

Résumé

Indemnisation sans égard à la faute consécutivité à des événements négatifs liés à la vaccination : évaluation des programmes internationaux

Les programmes qui fournissent une indemnisation sans égard à la faute dans le cas d'un événement négatif de vaccination ont été mis en place dans 19 pays du monde entier, le premier étant l'Allemagne en 1961 et le plus récent la Hongrie en 2005. Nous avons évalué ces programmes et déterminé les éléments qui leur étaient communs à tous : administration, financement, éligibilité, processus et prise de décision, norme de preuve, éléments d'indemnisation et droits relatifs aux litiges. La plupart de ces programmes sont gérés par les États ou les gouvernements nationaux, à l'exception de la Finlande et de la Suisse où ils sont coordonnés par les fabricants pharmaceutiques. Bien que le financement provienne généralement du ministère des Finances, la Chine (province de Chine, Taïwan) et les États-Unis d'Amérique imposent une taxe sur les doses de vaccin distribuées. Les décisions concernant l'indemnisation sont prises à l'aide de critères définis ou évalués au cas par cas, alors que la norme de preuve requise est généralement inférieure à celle nécessaire pour les procès. Les avantages liés aux programmes comprennent les frais médicaux, les prestations d'invalidité et les avantages liés aux pertes non économiques et aux décès. La majorité des pays permet aux requérants de demander des dommages et intérêts légaux en faisant appel aux tribunaux, au dédommagement par un programme d'indemnisation, mais pas les deux. Pour conclure, différents programmes, reposant sur des principes éthiques, ont été couronnés de succès et visibles du point de vue financier dans certains pays développés du monde entier. Nous pensons qu'il existe de bonnes raisons pour une vaste mise en œuvre de ces programmes dans d'autres pays développés.

Резюме

Компенсации за поствакцинационные осложнения: обзор международных программ

Программы, предусматривающие компенсацию без виновности, введены в 19 странах мира, начиная с Германии, где такая программа была внедрена в 1961 году, и кончая Венгрией, где она осуществляется с 2005 года. Мы провели обзор этих программ и выявили элементы, являющиеся для них общими: управление и финансовирование, право на получение компенсации, процедура подачи и рассмотрения заявления, уровень доказательности, элементы компенсации и право на возобуждение судебного иска. Управление программами в большинстве случаев осуществляется государством или местным органом власти, за исключением Финляндии и Швеции, где программы координируются производителями фармацевтической продукции. Хотя финансирование обычно производится из государственного бюджета, в Китае (Тайвань, провинция Китай) и в США действует налог на реализованные дозы вакцин. Решения о компенсации принимаются исходя из установленных критериев или на основе индивидуального рассмотрения каждого случая,

376

Resumen
Compensación sin admisión de responsabilidad tras las reacciones adversas atribuidas a la vacunación: revisión de los programas internacionales

Diecinueve países de todo el mundo han puesto en marcha diversos programas para ofrecer a sus ciudadanos compensaciones sin admisión de responsabilidad por las reacciones adversas tras la vacunación. El primero de ellos fue Alemania, en 1961 y el más reciente, Hungría, en 2005. Hemos revisado estos programas y hemos determinado qué elementos son comunes a todos ellos: administración y financiación, elegibilidad, proceso y toma de decisiones, acervo probatorio, elementos de compensación y derechos de litigio. La mayoría de los programas estaban gestionados por el Estado o por los Gobiernos de cada país, excepto en los casos de Finlandia y Suecia, donde estaban coordinados por los laboratorios farmacéuticos. Si bien la financiación suele proceder del Erario Público, China (provincia de Taiwán) y Estados Unidos de América gravan impuestos sobre las dosis de vacunas distribuidas.

Las decisiones sobre las compensaciones se adoptan siguiendo unos criterios establecidos o se evalúan en función de cada caso, mientras que el acervo probatorio necesario suele ser inferior al exigido para los casos que se elevan a los tribunales. Los beneficios que estos programas ofrecen incluyen gastos médicos, pensiones de invalidez y prestaciones por pérdidas no económicas y defunción. La mayoría de los países permite a los solicitantes reclamar daños y perjuicios ante los tribunales o un sistema de compensación monetaria, pero no ambas cosas. Hemos sacado en conclusión que, diversos países desarrollados en todo el mundo han aplicado con éxito varios programas económicamente viables basados en principios éticos. Creemos que hay razones más que suficientes para difundir la aplicación de estos programas en otros países desarrollados.

References
vaccine.2009.01.059 PMID:19200851